PMDA drug package insert
ダウノマイシン静注用20mg
PMDA Prescription drug · Meiji Seika ファルマ株式会社 · package insert Feb 10, 2026
Key facts
| Brand names | ダウノマイシン静注用20mg |
|---|---|
| Nonproprietary names | ダウノルビシン塩酸塩 |
| Companies | 製造販売元／Meiji Seika ファルマ株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 抗白血病・抗悪性腫瘍抗生物質製剤 |
| Therapeutic category codes | 874235 |
| YJ codes | 4235401D1035 |
| Approval numbers | 21900AMX00756000 |
| Package insert edition | 第3版 |
| Package insert date | Feb 10, 2026 |
| PMDA document key | 780009_4235401D1035_1 |
| PMDA company code | 780009 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- None Safety communications
- Yes PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: